Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
GLUE
#1873
Monte Rosa Therapeutics, Inc. Common Stock
17.750
0
-1.99%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
-1.99%
Monatliche Änderung
-23.16%
6 month change
+57.08%
Jahresänderung
+57.08%
Vorheriger Schlusskurs
18.110
0
Open
17.750
0
Bid
Ask
Low
17.750
0
High
17.750
0
Volumen
104
Märkte
Aktien
Gesundheitswesen
GLUE
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
46.63 M
49.36 M
50.15 M
61.51 M
—
Valuation ratios
Enterprise value
606.12 M
329.1 M
158.28 M
202.62 M
892.79 M
Price to earnings ratio
—
-3.38
-2.17
-7.08
63.44
Price to sales ratio
—
-1 113.42
526.89
6.78
14.34
Price to cash flow ratio
—
3.97
6.7
12.21
7.12
Price to book ratio
—
1.35
1.64
2.3
3.65
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
0.2
0.32
0.45
0.17
0.18
Return on equity %
0.21
0.4
0.76
0.33
0.27
Return on invested capital %
1 643.95
344.9
265.4
178.75
190.77
Gross margin %
100
100
100
100
400
Operating margin %
40.72 K
-34.06 K
25.73 K
107.26
355.73
EBITDA margin %
—
—
—
—
—
Net margin %
41.32 K
-32.88 K
24.3 K
96.14
298.16
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
20.96
10.79
5.07
2.4
21.71
Inventory turnover
—
—
—
—
—
Asset turnover
0
-0
0
0.2
0.46
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
1.96
0.85
0.57
-0.37
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
1.16
2.49
3.03
12.27
Net current asset value per share
—
5.84
4.6
5.11
17.63
Tangible book value per share
—
5.75
3.49
3.02
12.58
Working capital per share
—
5.3
3.69
2.98
13.54
Book value per share
—
5.75
3.49
3.02
12.58
Nachrichten
Monte Rosa-Aktie legt nach positiven Studiendaten zu Prostatakrebs zu
Monte Rosa shares rise on prostate cancer trial results
Monte Rosa: Positive Studiendaten zu Prostatakrebs-Wirkstoff MRT-2359
Monte Rosa reports positive trial data for prostate cancer drug
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
Monte Rosa: Piper Sandler erhöht Kursziel auf 37 US-Dollar/n
Monte Rosa stock price target raised to $37 from $27.50 at Piper Sandler
Monte Rosa Therapeutics platziert Kapitalerhöhung über 300 Millionen US-Dollar
Monte Rosa Therapeutics prices $300 million public offering
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
Monte Rosa Therapeutics startet öffentliches Angebot über 200 Millionen US-Dollar